Skip to main content
Top
Published in: Familial Cancer 2/2015

01-06-2015 | Original Article

Mutations of HNRNPA0 and WIF1 predispose members of a large family to multiple cancers

Authors: Chongjuan Wei, Bo Peng, Younghun Han, Wei V. Chen, Joshua Rother, Gail E. Tomlinson, C. Richard Boland, Marc Chaussabel, Marsha L. Frazier, Christopher I. Amos

Published in: Familial Cancer | Issue 2/2015

Login to get access

Abstract

We studied a large family that presented a strong familial susceptibility to multiple early onset cancers including prostate, breast, colon, and several other uncommon cancers. Through targeted gene, linkage, and whole genome sequencing analyses, we show that the presence of a variant in the regulatory region of HNRNPA0 associated with elevated cancer incidence in this family (Hazard ratio = 7.20, p = 0.0004). Whole genome sequencing identified a second rare protein changing mutation of WIF1 that interacted with the HNRNPA0 variant resulting in extremely high risk for cancer in carriers of mutations in both genes (p = 1.98 × 10−13). Analysis of downstream targets of the mutations in these two genes showed that the HNRNPA0 mutation affected expression patterns in the PI3 kinase and ERK/MAPK signaling pathways, while the WIF1 variant influenced expression of genes that play a role in NAD biosynthesis. This is a first report of variation in HNRNPA0 influencing common cancers or of a striking interaction between rare variants coexisting in an extended pedigree and jointly affecting cancer risk.
Appendix
Available only for authorised users
Literature
1.
go back to reference Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin—rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30(1):97–101CrossRefPubMed Abecasis GR, Cherny SS, Cookson WO, Cardon LR (2002) Merlin—rapid analysis of dense genetic maps using sparse gene flow trees. Nat Genet 30(1):97–101CrossRefPubMed
2.
go back to reference DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M et al (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43(5):491–498CrossRefPubMedCentralPubMed DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M et al (2011) A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43(5):491–498CrossRefPubMedCentralPubMed
3.
go back to reference Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J (1999) A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398(6726):431–436CrossRefPubMed Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM, Samos CH, Nusse R, Dawid IB, Nathans J (1999) A new secreted protein that binds to Wnt proteins and inhibits their activities. Nature 398(6726):431–436CrossRefPubMed
4.
go back to reference Liepinsh E, Banyai L, Patthy L, Otting G (2006) NMR structure of the WIF domain of the human Wnt-inhibitory factor-1. J Mol Biol 357(3):942–950CrossRefPubMed Liepinsh E, Banyai L, Patthy L, Otting G (2006) NMR structure of the WIF domain of the human Wnt-inhibitory factor-1. J Mol Biol 357(3):942–950CrossRefPubMed
5.
go back to reference Mazieres J, He B, You L, Xu Z, Jablons DM (2005) Wnt signaling in lung cancer. Cancer Lett 222(1):1–10CrossRefPubMed Mazieres J, He B, You L, Xu Z, Jablons DM (2005) Wnt signaling in lung cancer. Cancer Lett 222(1):1–10CrossRefPubMed
6.
go back to reference Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64(14):4717–4720CrossRefPubMed Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R, McCormick F, Jablons DM (2004) Wnt inhibitory factor-1 is silenced by promoter hypermethylation in human lung cancer. Cancer Res 64(14):4717–4720CrossRefPubMed
7.
go back to reference Myer VE, Steitz JA (1995) Isolation and characterization of a novel, low abundance hnRNP protein: A0. RNA 1(2):171–182PubMedCentralPubMed Myer VE, Steitz JA (1995) Isolation and characterization of a novel, low abundance hnRNP protein: A0. RNA 1(2):171–182PubMedCentralPubMed
8.
go back to reference San Lucas FA, Wang G, Scheet P, Peng B (2012) Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools. Bioinformatics 28(3):421–422CrossRefPubMedCentralPubMed San Lucas FA, Wang G, Scheet P, Peng B (2012) Integrated annotation and analysis of genetic variants from next-generation sequencing studies with variant tools. Bioinformatics 28(3):421–422CrossRefPubMedCentralPubMed
10.
go back to reference Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y (2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24(53):7946–7952CrossRefPubMed Taniguchi H, Yamamoto H, Hirata T, Miyamoto N, Oki M, Nosho K, Adachi Y, Endo T, Imai K, Shinomura Y (2005) Frequent epigenetic inactivation of Wnt inhibitory factor-1 in human gastrointestinal cancers. Oncogene 24(53):7946–7952CrossRefPubMed
11.
go back to reference Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A et al (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201(2):204–212CrossRefPubMed Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M, Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A et al (2003) WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 201(2):204–212CrossRefPubMed
Metadata
Title
Mutations of HNRNPA0 and WIF1 predispose members of a large family to multiple cancers
Authors
Chongjuan Wei
Bo Peng
Younghun Han
Wei V. Chen
Joshua Rother
Gail E. Tomlinson
C. Richard Boland
Marc Chaussabel
Marsha L. Frazier
Christopher I. Amos
Publication date
01-06-2015
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 2/2015
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-014-9758-8

Other articles of this Issue 2/2015

Familial Cancer 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine